Searching for semaglutide 14 mg? Here's what the dose numbers really mean

You've read '14 mg semaglutide' somewhere, here's where it comes from

Imagine you're researching oral semaglutide, you spot a product list, and you see 3 mg, 7 mg and 14 mg. Those numbers are real. They belong to Rybelsus, which Novo Nordisk also makes from semaglutide, and which has been available in the UK for several years. Rybelsus is prescribed by GPs and diabetes specialists for blood-sugar control in adults with type 2 diabetes. It works. For that purpose, it is appropriate.

The problem is that the two medicines (Rybelsus for diabetes and Wegovy tablets for weight loss) share the same active ingredient but carry entirely separate UK licences, separate dose schedules and separate clinical trials behind them. Searching for one when you need the other is a reasonable mistake, because most search results do not distinguish them clearly. The MHRA licenses UK medicines specifically, and the 14 mg semaglutide strength simply does not appear in any UK weight-management approval.

Worth doing right now: check the name on the box of any semaglutide medicine you are considering. Rybelsus says Rybelsus. Wegovy says Wegovy. The strength on the label will tell you immediately which product and licence you are looking at. That single check takes about ten seconds and could save considerable confusion.

What the licensed Wegovy tablet doses actually look like

The Wegovy tablet schedule was set by Novo Nordisk's clinical programme and confirmed when the MHRA approved the medicine on 11 June 2026, making it the first oral GLP-1 treatment for weight loss licensed anywhere in Europe. The dose escalation runs from 1.5 mg through intermediate steps to a 25 mg maintenance dose, with at least one month at each level before increasing. That slow escalation is intentional: most of the gastrointestinal side effects (nausea, loose stools, indigestion) are dose-dependent, and giving the gut time to adjust makes them more manageable.

The maintenance dose of 25 mg is considerably higher than anything in the Rybelsus range. That is not an error; it reflects the fact that oral bioavailability of semaglutide is low, so a higher tablet dose is needed to deliver a therapeutically equivalent amount. Patients already stable on the Wegovy injection at 2.4 mg weekly may, subject to prescriber assessment, move directly to the 25 mg tablet. If you want to understand the full Wegovy dose progression, that page walks through each stage in detail.

Trial evidence from the OASIS 4 phase 3 study (307 adults over 64 weeks) showed an average weight reduction of around 13.6% with the 25 mg tablet against roughly 2.4% for placebo, both alongside lifestyle changes. Among those who stayed fully adherent to treatment, the figure rose to around 17%. The NHS has not yet appraised Wegovy tablets through NICE, so at launch this is a private prescription medicine only.

Rybelsus 14 mg: what it is and why it does not cross over to weight loss

Rybelsus 14 mg is the maximum dose in the diabetes schedule: patients start at 3 mg for one month, move to 7 mg, and then to 14 mg if further blood-sugar control is needed. The 3 mg starting dose exists purely for gastrointestinal tolerance, not for any glucose-lowering effect. At 14 mg some patients do lose weight as a secondary effect, because semaglutide reduces appetite regardless of licence. But that is a side effect of a diabetes medicine, not a licensed weight-management treatment, and it is not what Rybelsus is approved for. A prescriber assessing you for weight loss would not prescribe Rybelsus 14 mg for that purpose under UK law.

The semaglutide maintenance dose page covers how long-term dosing works once the right medicine and schedule are established. The broader weight-loss treatment landscape is worth reading if you are still deciding between injection and tablet options. Context on what private Wegovy treatment costs is also available if pricing is part of the decision.

If semaglutide for weight loss is what you actually need

The licensed routes are clear. Wegovy injection (once weekly, up to 2.4 mg or 7.2 mg) and Wegovy tablets (once daily, up to 25 mg) are both approved by the MHRA for adults with a BMI of 30 or above, or 27 to 29.9 alongside a weight-related health condition such as high blood pressure or high cholesterol. Both are prescription-only medicines, a clinical assessment by a registered prescriber is required before any supply, and the prescriber decides which option and which starting dose is right for you personally.

The 2 mg dose context page explains some of the nuances around where different semaglutide strengths sit, and the NHS medicines page for semaglutide covers side effects and safety information you should read before starting. At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber (a real clinician, not automated software) and dispatched the same day when approved. If Wegovy tablets or the Wegovy injection might be right for you, the place to begin is a consultation rather than a dose comparison.

Speak to our prescribers via a free consultation and they will confirm whether semaglutide is clinically suitable for your situation, and which form and schedule makes most sense.